Insurance Strategy & Advisory
Solvency II Update
Unlisted Equities, Long-term Equity Investments and Unrated Debt

Based on the technical advice of EIOPA, the European Commission (EC) delegated regulation of 8.3.2019 amends the Solvency II regulation in different areas. Most notably, from an investment management perspective, the capital charges for qualifying investments in long-term equities, unlisted equity and unrated debt have been reduced.

Main Takeaways

**Unlisted equity**
Certain investments in unlisted equities may be eligible for a treatment as type 1 equities, allowing for a reduced capital charge of 39% compared to 49% for type 2 equities. Aside from a range of qualitative and diversification conditions, the equity investment need to show a low beta coefficient on a portfolio level. Since it is not possible to calculate a beta based on the unlisted equities return (since they are not listed), a formula based on financial ratios is defined to approximate beta. The new provisions are mainly relevant for direct private equity investments while many investments via funds may already subject to a type 1 equity charge.

**Long-term equity investments**
Long-term investments in equities with an average holding period of more than 5 years can benefit from the same capital charge as strategic participations, given that specific criteria regarding asset-liability and risk management are met. Long-term equities and strategic participations are subject to a favorable capital charge of 22% without an asymmetric adjustment. The fact that a long-term equity portfolio must be assigned to a specific pool of insurance obligations over the entire lifetime of these obligations may limit the applicability to a smaller group of insurer, e.g. insurers in the UK or Spain that also use the matching adjustment or France where the liability structure is more favourable. The concept of long-term equity investments is very similar to the duration-based equity risk sub-module.

**Unrated debt**
Unrated bonds and loans with proven quality can be assigned to a credit quality step (CQS) of either 2 or 3 (corresponding to an ‘A’ or ‘BBB’ rating). The Spread SCR for those bonds will decrease by up to 20 percentage points if a bond or loan can qualify as such. There are two different ways for loans to qualify. The first is based on an internal credit assessment taking into account qualitative and quantitative factors. This internal credit assessment is a complex process which may require a substantial amount of research. The alternative way is for an insurer co-invests into a loan with a bank if the bank discloses sufficient information on the credit quality and methodology of the credit assessment to the insurer. However, we deem this challenging since banks would probably be reluctant to share this kind of information.

Summary

Marlon Rockenfeller
Head of Insurance Strategy & Advisory, EMEA & APAC

Thomas Gillmann
Insurance Strategy & Advisory, EMEA & APAC
Unlisted equity

Under the amended regulation, certain investments in unlisted equities can qualify for a treatment as type 1 equities, subject to a 39% capital requirement compared to 49% for type 2 equities. The table below specifies the criteria that unlisted equity portfolios have to meet in order to be treated as type 1 equities.

Investments via unleveraged closed-ended EU-AIFs, for which a look-through is possible, are always treated as type 1 equities regardless of the underlying private equity portfolio. Hence, the new provision is mainly relevant for direct investments in private equity which typically only make up a smaller portion of an insurer’s private equity portfolio. Therefore, this provision should have a limited impact on insurers and asset managers alike.

The approach to approximate the beta of unlisted equity is based on a regression of listed non-financial stocks from the STOXX® Europe 600 Index. The regression suggested the coefficients in the formula below. The four variables have been determined by EIOPA as the ones with a significant influence on beta. The underlying assumption here is that a company’s risk profile does not materially change whether it’s public or private. The portfolio beta is the average of all individual betas (as calculated using the formula below) weighted by the book value of the equity stakes.

The beta of a qualifying unlisted equity portfolio must not exceed 0.796.

As with unrated debt, EIOPA proposes that the total amount of unlisted equity and unrated debt which is treated preferably through the aforementioned approaches is limited to 5% of the overall investment portfolio. However, the European Commission decided not to follow this proposal. Hence, the amount of unlisted equity and unrated debt with a preferential treatment will remain unregulated.

\[ \beta = 0.9478 - 0.0034 \times \text{Avg Gross Margin} + 0.0139 \times \left( \frac{\text{Total Debt}}{\text{Avg CFO}} \right) - 0.0034 \times \text{Avg ROCE} \]

Long-term equity investments

Not only qualified unlisted equities can benefit from a reduced capital charge but also long-term investments in equities (listed or unlisted) are eligible for a significantly reduced capital requirement of 22%. In this way, long-term equity investments are treated in the same way as strategic partnerships. To be considered as a long-term equity investment, the average holding period must be at least 5 years and specific criteria regarding asset-liability management as well as risk and investment management must be met. Most importantly, a long-term equity portfolio must cover a clearly defined pool of insurance obligations over the entire lifetime of these obligations.

The concept of long-term equity investments is very similar to the duration-based equity risk sub-module. In general, only equity instruments listed in the EEA or unlisted equities of companies with their head offices in the EEA are eligible for a favorable treatment. Where equities are held within a fund, the criteria mentioned above are assessed at the level of the fund and not of the underlying assets.
The Solvency II Equity Risk Module has become more granular offering capital reliefs for certain type of equity investments (see table below)

**FIGURE 4. CAPITAL CHARGES FOR DIFFERENT TYPE OF EQUITY INVESTMENTS**

<table>
<thead>
<tr>
<th>Equity Type I (listed EEA/OECD)</th>
<th>Stress (in %)</th>
<th>Symmetric Adjustment (SA)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Equity Type II (listed non-EEA/OECD)</td>
<td>49%</td>
<td>100%*SA</td>
</tr>
<tr>
<td>Qualifying infrastructure equity</td>
<td>30%</td>
<td>77%*SA</td>
</tr>
<tr>
<td>Qualifying infrastructure corporate equity</td>
<td>36%</td>
<td>92%*SA</td>
</tr>
<tr>
<td>Strategic participations</td>
<td>22%</td>
<td>-</td>
</tr>
<tr>
<td>Long-term equity investments (listed or unlisted)</td>
<td>22%</td>
<td>-</td>
</tr>
<tr>
<td>Qualifying unlisted equity portfolios</td>
<td>39%</td>
<td>-</td>
</tr>
<tr>
<td>Unlisted equity (unqualified)</td>
<td>49%</td>
<td>100%*SA</td>
</tr>
</tbody>
</table>

*Variable component of the equity risk charge ranging between +/-10%

We believe that the favorable treatment of unlisted equity can further drive the attractiveness of this asset class for insurers, also taking into account the beneficial return profile of private equity investments. However, the new provisions are mainly relevant for direct private equity investments while most investments via private equity funds may already be subject to a type 1 equity charge. Additionally, the reduced capital charge for long-term equity investments can drive insurer’s allocations to equities in general. But the fact that long-term equity portfolios must be assigned to a clearly identified pool of the insurance obligations over the entire lifetime of these obligations may limit the applicability to a smaller group of insurer, e.g. insurers with UK-like annuity business.

**Unrated debt**

Given certain quality conditions, unrated debt instruments can be assigned to a credit quality step (CQS) of either 2 or 3, which corresponds to a “A” or “BBB” rating. This way, the Spread SCR on unrated debt may be reduced by up to 20 percentage points.

For a bond to be eligible for the preferred treatment, two assessment approaches are available:

_ The Internal Assessment Approach &
_ The use of approved internal banking models.

**FIGURE 5. UNRATED BONDS VS. CQS 2 / CQS3**

**Internal Assessment Approach**

Under the Internal Assessment Approach, following criteria need to be fulfilled to allow for A or BBB spread risk capital charge for unrated debt:

_ **Borrower characteristics**: The borrower must be a limited liability company with headquarter in the EEA meeting certain criteria regarding financial ratios, credit history and reporting
_ **Debt instrument**: Additional conditions regarding the structure of the debt instrument must be met, e.g. senior debt
_ **Internal process**: An internal process has to classify the bond as eligible for preferred treatment, taking into account a variety of qualitative and quantitative factors
_ **Comparable yield criterion**: The yield of the bond must not be substantially higher than that of a broad market index with corresponding currency and maturity. The distance to the market yield determines if an unrated bond receives an A or BBB rating capital charge (see Figure 6 and 7).

**FIGURE 6. BROAD MARKET INDICES**

*As of 1st of April 2019; Source: Bloomberg LP*
Although information in this document has been obtained from sources believed to be reliable, we do not guarantee its accuracy, completeness or fairness, and it should not be relied upon as such. The information herein reflects our current views only, are subject to change, and are not intended to be promissory or relied upon by the reader.

**Approved Internal Bank Models**

When a bank provides a loan to a **corporate** and lets an insurer co-invests into that loan, preferable treatment is possible, however tied to strict rules regarding **disclosure of information about the loan**. Specifically, the bank has to **provide transparency and detailed information on the internal model** used to evaluate the loan. Furthermore, the bank is required to **keep at least 20% of the nominal value** of the bond. If the bank decided to provide the required information to an insurer, a **Probability of Default** (determined by the bank) will be converted into a CQS, which the insurer can use.

We believe that banks will typically be unwilling to provide the necessary information to insurance companies, essentially allowing the insurer to outsource the credit analysis. The Internal Assessment Approach appears more feasible, although it does require substantial initiative and resource devotion to comply with all criteria if an internal rating approach is not already established. Especially since the Internal Assessment Approach is in part based on qualitative assessment, insurance undertakings should carefully consider if the additional gain they could achieve through preferential SCR treatment compensates for the costs associated with the process. Additionally, the requirements under the internal assessment approach clearly limit the securities which are potentially eligible to those which from a risk and return profile are trading in line with a A or BBB rating. This classification is completely unrelated to private debt or direct lending. The idea here is to enable lending to SMEs on an unrated basis where quality is sufficient and to facilitate the private placement market across Europe. This is the first step away from the reliance on rating agencies shifting towards internal rating processes.

**Other material changes**

Besides the discussed changes related to capital charges for certain type of investments in equities and unrated debt, the EC regulation also amends Solvency II in many other areas. The most material changes include:

- Bonds and loans that are fully, unconditionally and irrevocably guaranteed by an EU member state’s **regional government or local authority (RGLA)** can benefit from a reduced capital charge of up to 0%. This way, Solvency II is aligned with banking regulation.
- The recognition of **risk-mitigation techniques** has been further refined to reflect common practices in risk management. For example, the minimum maturity for derivatives to be used in hedge programs has been reduced to one month.
- Going forward, an investment fund’s **last reported asset allocation** can be used to calculate the capital charge for those funds for which a look-through or target allocation is not available. For the purpose of that calculation, data groupings may be used but only for 20% of an insurer’s assets. Under the amended regulation, unit-linked assets will be **excluded when calculating the 20% limit**.
- **All derivatives** – weather used for hedging or other purposes – are now treated as type 1 exposures in the **counterparty default risk module**.
- **Some risk calibration parameters** for non-life premium and reserve risk, and health and non-life catastrophe risk have been updated to reflect additional data gathered since the last calibration.
For Institutional investor and Registered Representative use only. Not to be shared with the public.

The brand DWS represents DWS Group GmbH & Co. KGaA and any of its subsidiaries such as DWS Distributors, Inc. which offers investment products or Deutsche Investment Management Americas Inc. and RREEF America L.L.C. which offer advisory services.

The material was prepared without regard to the specific objectives, financial situation or needs of any particular person who may receive it. It is intended for informational purposes only and it is not intended that it be relied on to make any investment decision. It is for professional investors only. It does not constitute investment advice or a recommendation or an offer or solicitation and is not the basis for any contract to purchase or sell any security or other instrument, or for Deutsche Bank AG and its affiliates to enter into or arrange any type of transaction as a consequence of any information contained herein.

Please note that this information is not intended to provide tax or legal advice and should not be relied upon as such. DWS does not provide tax, legal or accounting advice. Please consult with your respective experts before making investment decisions.

Neither DWS nor any of its affiliates, gives any warranty as to the accuracy, reliability or completeness of information which is contained.

Except insofar as liability under any statute cannot be excluded, no member of DWS, the Issuer or any officer, employee or associate of them accepts any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission or for any resulting loss or damage whether direct, indirect, consequential or otherwise suffered.

This document is intended for discussion purposes only and does not create any legally binding obligations on the part of DWS and/or its affiliates. Without limitation, this document does not constitute investment advice or a recommendation or an offer or solicitation as a consequence of any information contained herein. The information contained in this document is based on material we believe to be reliable; however, we do not represent that it is accurate, current, complete, or error free. Assumptions, estimates and opinions contained in this document constitute our judgment as of the date of the document and are subject to change without notice. Past performance is not a guarantee of future results. Any forecasts provided herein are based upon our opinion of the market as at this date and are subject to change, dependent on future changes in the market. Any prediction, projection or forecast on the economy, stock market, bond market or the economic trends of the markets is not necessarily indicative of the future or likely performance. Investments are subject to risks, including possible loss of principal amount invested.

Certain DWS products and services may not be available in every region or country for legal or other reasons, and information about these products or services is not directed to those investors residing or located in any such region or country.

The material was prepared without regard to the specific objectives, financial situation or needs of any particular person who may receive it. It is intended for informational purposes only and it is not intended that it be relied on to make any investment decision. It is for professional investors only. It does not constitute investment advice or a recommendation or an offer or solicitation and is not the basis for any contract to purchase or sell any security or other instrument, or for DWS to enter into or arrange any type of transaction as a consequence of any information contained herein. The information contained in this document is based on material we believe to be reliable; however, we do not represent that it is accurate, current, complete, or error free. Assumptions, estimates and opinions contained in this document constitute our judgment as of the date of the document and are subject to change without notice. Past performance is not a guarantee of future results. Any forecasts provided herein are based upon our opinion of the market as at this date and are subject to change, dependent on future changes in the market. Any prediction, projection or forecast on the economy, stock market, bond market or the economic trends of the markets is not necessarily indicative of the future or likely performance. Investments are subject to risks, including possible loss of principal amount invested.

Past performance is not indicative of future results. No representation or warranty is made as to the efficacy of any particular strategy or the actual returns that may be achieved.

For investors in Bermuda: This is not an offering of securities or interests in any product. Such securities may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally, non-Bermudian persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable Bermuda legislation.